The First Trust Health Care AlphaDEX Fund (NYSEArca: FXH), which features Salix and Actavis as its fifth- and seventh-largest holdings, respectively, is higher by nearly 2% today as well. Salix, Actavis and Allergan, in that order, combine for over 7% ofFXH’s weight.

Adding some intrigue to the notion of a Salix takeover, one institutional trading desk said there is solid activity today in the Salix November $170 call options. The stock would need to rise nearly 10% to provide profits for buyers of those calls.

The iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE), which allocates a combined 8.6% of its weight to Actavis and Salix, is up 1.8% on volume that is already more than 40% above the daily average.

PowerShares Dynamic Pharmaceuticals Portfolio

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.